Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
Primary cilia accumulation in aged gingival tissue drives fibroblast senescence and periodontal inflammation. Suppressing ciliogenesis reverses this process through AKT signaling activation, offering a mechanistic target for managing age-related gum disease and tissue deterioration.
A senolytic vaccine combined with mesenchymal stem cells produced synergistic reductions in inflammatory markers and improved regenerative capacity in acute liver injury and chemotherapy-induced senescence models in mice. The findings suggest that removing senescent cells may create a more permissive environment for stem cell function, though the evidence derives from artificially induced injury rather than natural aging.
The first major US longevity policy summit convened federal regulators, researchers, and lawmakers to address the regulatory and funding barriers slowing longevity science translation. The convergence signals political recognition that healthspan improvement represents a national priority rather than a niche scientific interest.
Maryland's Longevity Ready Act embeds a 10-year aging strategy into state law and establishes an Aging Resilience Fund, requiring sustained coordination across government agencies rather than allowing policy to shift with election cycles. The legislation recognizes that demographic change — with one in four residents aged 60+ by 2030 — demands infrastructure, housing, transportation, and financial planning changes that transcend traditional healthcare silos.
Lys Therapeutics has raised $29 million to advance LYS241, a blood-brain barrier-protective therapy designed to treat both acute stroke and chronic Parkinson's disease by reinforcing neural infrastructure rather than addressing symptoms after damage occurs. This approach represents a fundamental shift from treating individual neurological diseases toward addressing the shared biological mechanism of barrier dysfunction that underlies multiple conditions.
Kenai Therapeutics has completed enrollment in a Phase 1b/2a trial of RNDP-001, an allogeneic cell therapy designed to replace dopaminergic neurons lost in Parkinson's disease. The trial will assess safety, tolerability, and preliminary efficacy in patients with moderate to moderate-severe idiopathic Parkinson's, with results expected to clarify whether cell replacement can restore motor and cognitive function in neurodegenerative disease.
FibroBiologics has completed manufacturing of a third batch of CYWC628, an allogeneic fibroblast cell therapy for diabetic foot ulcers, positioning the company to complete its Phase 1/2 trial with interim efficacy data expected in Q3 2026. The therapy targets a major complication of diabetes where conventional wound healing approaches often fail, addressing both tissue regeneration and the chronic inflammatory environment that impairs healing in diabetic patients.
A seven-day pilot study of 40 women found that Basis supplementation correlated with self-reported reductions of 50% or more in hot flashes, bloating, and sleep disruption, alongside a statistically significant shift in estradiol-to-estrone ratio favoring estradiol dominance. The mechanism appears linked to NAD+ metabolism and estrogen balance during the menopausal transition.
Insilico Medicine projects revenue growth exceeding 270% to $102.5–$106.5 million by mid-2026, driven by expanding pharmaceutical partnerships and AI platform capabilities. This trajectory reflects accelerating commercial validation of generative AI for drug discovery and development—a structural shift in how compounds are identified, optimized, and brought to clinical stages.
Amprion secured multi-million-dollar growth funding to expand diagnostic capacity for synucleinopathies—neurodegenerative diseases including Parkinson's, Lewy body dementia, and Alzheimer's. Early detection of these diseases through seed-amplification assays shifts intervention timing from symptomatic to preclinical stages, a critical advantage in slowing neurodegeneration.
Embodied aging simulation—where younger adults physically experience mobility and sensory restrictions—shifts their psychosocial understanding of older adults and increases empathy-driven behavioral change. This finding demonstrates that perspective-taking rooted in somatic experience produces measurable differences in attitudes toward aging compared to information-based learning alone.
Social and economic resources in midlife predict who will become caregivers in later life, revealing that caregiving capacity is stratified by current opportunity and constraint rather than distributed randomly across the population. This has direct implications for long-term care planning and understanding how resource disparities compound across the lifespan.